Novo Nordisk A (NVO) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access NVO Annual Income Statement →
The income statement data below highlights shifts in Novo Nordisk A's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue46,820.32
Costs & Expenses
Cost of Goods and Services Sold8,905.84
Gross Profit37,914.49
Depreciation & Amortization5,551.83
Research and Development Expense-7,883.42
OtherOperating Income Expense-45.45
Total operating costs including COS27,481.32
Operating income / -loss19,339.00
Net Interest (-)Expense / Income0.00
Other loss / -income-436.60
Total costs & expenses27,044.73
Income & Taxes
Income / -loss before income taxes19,775.60
Income taxes expenses / -benefit4,257.80
Income after income taxes15,517.80
Income / -loss from continuing operations15,517.80
Net income / -loss15,517.80
Income / -loss to shareholder15,517.80
EBIT19,775.60
EBITD23,203.05
EBITDA23,203.05
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Novo Nordisk A income statement history.

About NVO Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.